WS-7338, produced by Streptomyces sp. No. 7338, was found to be a competitive and specific antagonist against ET-1 receptors in in vitro studies and WS-7338Bis also active in vivo. Furthermore, WS-7338 B was a specific antagonist for vascular ET-1 receptors (ETA receptors) and significantly prevented the accumulation of intracellular inositol 1,4,5-triphosphate (IP3) in endothelin treated rat aorta tissues. In this paper, we described the ET-1 antagonistic activity of WS-7338 B. The results indicated that WS-7338B can displace the binding ofET-1 at all receptor sites in rat aorta and human aorta. Moreover, WS-7338 B can attenuate the second messenger (inositol 1,4,5-triphosphate (IP3)) production induced by ET-1.
WS-7338, produced by Streptomyces sp. No. 7338, was found to be a competitive and specific antagonist against ET-1 receptors in in vitro studies and WS-7338Bis also active in vivo. Furthermore, WS-7338 B was a specific antagonist for vascular ET-1 receptors (ETA receptors) and significantly prevented the accumulation of intracellular inositol 1,4,5-triphosphate (IP3) in endothelin treated rat aorta tissues. 83 Three distinct human ET related genes have been identified, coding for peptides, ET-1, ET-2 and ET-31}. Endothelial cells can only release ET-1. The expression of ET-2 has not been demonstrated to be physiological in any normal tissue yet, while ET-3-like immunoreactive material has been found in porcine brain homogenate2). Intravenously infused ET-1 induces a profound pressor effect3), suggesting a potential role for ET-1 in the pathogenesis of systemic hypertension. Furthermore, ET-1 may have a possible role in development of cerebral vasospasm after subarachnoid hemorrhage4), myocardial infarction5) and acute renal failure6). The precise pathological mechanism of action of ET-1 is not known. The presence of ET-1 binding sites in blood vessels and in several organ systems suggests ET-1 may have important regulatory functions.
In this paper, we described the ET-1 antagonistic activity of WS-7338 B. The results indicated that WS-7338B can displace the binding ofET-1 at all receptor sites in rat aorta and human aorta. Moreover, WS-7338 B can attenuate the second messenger (inositol 1,4,5-triphosphate (IP3)) production induced by ET-1.
Materials and Methods ET Receptor Assay ET receptor binding assay was described in detail in a preceding paper7). Receptors of porcine brain membranes, kidney membranes, lung membranesand humanaorta membraneswere prepared in the same procedures mentionedin the samepaper7).
Rabbit Aorta Constriction In Vitro Thoracic aorta were isolated from freshly sacrificed male albino rabbits (1 1 weeks old) and cut into 2mmwidth and 25 mmlength of arterial segments. The tissues were suspended in 25 ml organ chambers filled with Krebs-Ringer solution (113mM NaCl, 4.8mM KC1, 2.2him glucose) maintained at 37°C and gassed with 95% O2/5% CO2. A preload of 1 g was applied after the aorta had been conditioned by application of increasing concentration of KC1. Contractions were measured as an increase in isometric tension. WS-7338B was tested against the contractile response of ET-1 (3.2 x 10"9 m). Synthetic ET-1 was purchased from Peptide Institute Inc. (Osaka, Japan). WS-7338 B was added after the full contractile response induced by ET-1.
Measurement of Inositol Phosphates
The tissue level ofinositol monophosphate (IP) was determined by a slight modification of the procedure of Michael J. Berridge (1983)8). Briefly, rings of rats aorta were incubated at 37°C for 3 hours in Krebs solution containing mjFo-[2-3H]inositol(4 iuCi/0.5 ml for 1 ring). mjo-[2-3H]Inositol was purchased from NewEngland Nuclear (15 Ci/mmol). The tissues were transferred into Krebs solution containing lOmM LiCl and placed on ice for 30 minutes. ET-1(3 x 10~9 m) andWS-7338 B (10~4m) were added to the solution and the mixture was incubated at 37°C for 60 minutes. Each tissue was then homogenized in 1.0ml of 10%trichloroacetic acid with a Pyrex-glass homogenizer. The homogenates were centrifuged at 300 x g for 15 minutes and the supernatants were extracted 3 times with 2.0ml ofether. Four ml of 5 mMNaHCO3 was added to 1 ml of the aqueousphase and the mixture was transferred to a columncontaining anion exchange resin (Bio-Rad AGI-X8, 100~200mesh, formate form). The column was washed with 10ml of water to remove free mjo-[2-3H]inositol.
Labeled ray<9-[2-3H]inositol phosphates (IP1? IP2 and IP3) were eluted by the stepwise addition of 6 ml of solutions containing increasing levels of ammoniumformate, IPj was eluted with 0.1 m formic acid plus 0.2m ammoniumformate, for IP2 0.1 m formic acid plus 0.4m ammoniumformate was used and for IP3 0.1 m formic acid plus 1.0m ammoniumformate. Scintillation cocktail (Aquasol-2, NewEngland Nuclear) was added to the eluate and the samples were counted in a liquid scintillation counter (Packard TRI-CARB 4530). 
Results and Discussion
High-affinity binding site for ET-1 were present in porcine aorta membranereceptors. Scatchard analysis of the binding data in the porcine aorta revealed a straight line, indicating a single class of binding site and the equilibrium dissociation constant was 0.38 x 10~9m, the maximal specific binding was 250fmol/mg protein (Fig. 1) .
We demonstrated specificity of WS-7338 B for antagonism of binding in the receptor membranes of lung, aorta, kidney and brain (Table 1) .
WS-7338 B is a specific aorta ET-1 antagonist.
Moreover, WS-7338B was shown to be active in the humanaorta receptor membranesbinding assay, with an IC50 value of 4.9x 10~7m (Table 1) . However, WS-7338 B had no affinity for the FGF receptors, angiotensin II (Ang II) receptors, bradykinin (BK) receptors and substance P (SP) receptors (Table 2 ). These results suggest that WS-7338 B is a selective antagonist for ET-1 at the vascular aorta membrane receptors.
Inhibition of ET-1 binding in the porcine aorta membanereceptors by WS-7338B was shown to be competitive in the Lineweaver-Burk plot (Fig. 2) . The Ki value was calculated as 5.1 x 10"7m from the Dixon plot (Fig. 3) . The dose-response curve for WS-7338B against 3.2 x 10~9m ET-1-induced rabbit aorta constriction was studied in drug pretreatment experiments (Fig. 4) . WS-7338 A inhibited ET-1-induced rabbit aorta constriction in a dose-dependent manner.
The current view is that ET-1 binds to a specific membrane receptors, leading to intracellular biochemical signals involving the activation of inositol phosphates and diacylglycerol and the elevation of calcium levels from intracellular calcium stores9). In this respect, we demonstrated the ET-1 -induced increase of inositol phosphates (IP1? IP2 and IP3) in rat aorta rings, and the inhibition of this increase by the ET-1 antagonist WS-7338 B. Inositol phosphates (IPl9 IP2 and IP3) formation was blocked by WS-7338 B in a similar intensity (Fig. 5) . The concentrations of ET-1 and WS-7338B used in rabbit aorta contractile response experiments (Fig. 4) were almost same that used in the inositol phosphate formation experiments (Fig. 5) . Thus IP3 formation blocking activity may be an essential element for ET-1 receptor antagonism.
Most recently ET receptors were classified into three distinct subclasses (ETA, ETBand ETC) on the basis of agonist affinities (ET-l >ET-3; ET-l =ET-3; ET-3>ET-1). It was recommended that an ET-1 specific type be called ETAreceptors, nonselective receptors be named ETBand ET-3 specific receptors be designated ETc10'11*. A large amount of ETBreceptors are expressed in lung, kidney and brain, on the other hand, vascular aorta tissues express ETAreceptors12'13*. As shown in Table 1 , WS-7338 B is active against aorta receptors but not against lung, kidney and brain receptors. These findings suggest that WS-7338B is an ETAspecific receptor antagonist.
Intravenous bolus injection of ET-1 cause a transient depressor response (based on ETBreceptor) followed by a sustained pressor response (based on ETAreceptor). In the in vivo evaluation experiment, ET-1 (3.2/zg/kg) is given intravenously to SHR rats 10 minutes after administration of WS-7338 B (10 mg/kg iv). Pretreatment with 10 mg/kg of WS-7338 B reduces the pressor effect ofET-1 (55% inhibition), in contrast WS-7338B has no effect on the depressor response of ET-1. The results of the in vivo study are in agreement with the data given by the in vitro receptor binding studies (Table 1) mentioned above.
In conclusion, it may be worthwhile investigating the chemical modification of WS-7338B in order to increase the ETAreceptor specific antagonism activity or to study the structure-activity relationships of derivatives of this unique lead compound. Our final goal is to create a more potent ET antagonist in 
